Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study.
Gori S, Fabi A, Angiolini C, Turazza M, Salvini P, Ferretti G, Cretella E, Gianni L, Bighin C, Toss A, Zamagni C, Vici P, De Rossi C, Russo A, Bisagni G, Frassoldati A, Borgato L, Cariello A, Cappelletti C, Bordonaro R, Cinieri S, Modena A, Valerio M, Alvisi MF, De Simone I, Galli F, Rulli E, Santoni A, Nicolis F. Gori S, et al. Among authors: frassoldati a. Cancers (Basel). 2023 Oct 4;15(19):4852. doi: 10.3390/cancers15194852. Cancers (Basel). 2023. PMID: 37835546 Free PMC article.
Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group. Franceschi E, et al. J Neurooncol. 2018 Jan;136(1):221-222. doi: 10.1007/s11060-017-2638-y. J Neurooncol. 2018. PMID: 29124650
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.
Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R. Del Re M, et al. Among authors: frassoldati a. Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156777 Free PMC article.
The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
Franceschi E, Tosoni A, Minichillo S, Depenni R, Paccapelo A, Bartolini S, Michiara M, Pavesi G, Urbini B, Crisi G, Cavallo MA, Tosatto L, Dazzi C, Biasini C, Pasini G, Balestrini D, Zanelli F, Ramponi V, Fioravanti A, Giombelli E, De Biase D, Baruzzi A, Brandes AA; PERNO Study Group. Franceschi E, et al. World Neurosurg. 2018 Apr;112:e342-e347. doi: 10.1016/j.wneu.2018.01.045. Epub 2018 Jan 11. World Neurosurg. 2018. PMID: 29337169
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Del Re M, Cucchiara F, Rofi E, Fontanelli L, Petrini I, Gri N, Pasquini G, Rizzo M, Gabelloni M, Belluomini L, Crucitta S, Ciampi R, Frassoldati A, Neri E, Porta C, Danesi R. Del Re M, et al. Among authors: frassoldati a. Cancer Immunol Immunother. 2021 Jun;70(6):1667-1678. doi: 10.1007/s00262-020-02810-6. Epub 2020 Dec 14. Cancer Immunol Immunother. 2021. PMID: 33315149 Free PMC article.
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study.
Lupini L, Roncarati R, Belluomini L, Lancia F, Bassi C, D'Abundo L, Michilli A, Guerriero P, Fasano A, Tiberi E, Salamone A, Cosi DM, Saccenti E, Tagliatti V, Maestri I, Sabbioni S, Volinia S, Gafà R, Lanza G, Frassoldati A, Negrini M. Lupini L, et al. Among authors: frassoldati a. Int J Mol Sci. 2022 Aug 1;23(15):8546. doi: 10.3390/ijms23158546. Int J Mol Sci. 2022. PMID: 35955679 Free PMC article.
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D. Baldini E, et al. Among authors: frassoldati a. Lung Cancer. 2020 Feb;140:59-64. doi: 10.1016/j.lungcan.2019.12.014. Epub 2019 Dec 20. Lung Cancer. 2020. PMID: 31881412
160 results